Here are seven things to know:
1. The combined cash flow and growth opportunities show a suggested valuation of more than $100 per share. The company is currently trading at $77 per share.
2. There is an $850 million in pre-tax synergies that is expected to further increase the company’s valuation.
3. The management’s goal is to return 50 percent of free cash flow to shareholders.
4. The current Intrinsic Market Value of $149 billion with 1.436 billion shares outstanding.
5. The “old” Medtronic’s revenues are expected to grow 6+ percent and Covidien is expected to grow revenues at 5+ percent through 2019.
6. There are some potential risks for the company, including the failure to integrate the two businesses and industry consolidation among competitors that could increase competition.
7. Healthcare policy and regulatory changes could have an impact on Medtronic’s future growth; the tax law changes for multinational corporations are another factor to consider as well as product liability claims.
More articles on orthopedic devices:
Greatbatch short interest drops by 8.5% — 4 things to know
Amedica to present CASCADE clinical results
Spine device stock report: 5 key companies
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
